Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma

Hutson, Thomas E., Davis, Ian D., Machiels, Jean-Pascal H., De Souza, Paul L., Rottey, Sylvie, Hong, Bao-fa, Epstein, Richard J., Baker, Katherine L., McCann, Lauren, Crofts, Theresa, Pandite, Lini, Figlin, Robert A.·2010·Journal of Clinical Oncology

Abstract

Purpose: Inactivation of the von Hippel-Lindau gene in clear-cell renal cell carcinomas (RCC) leads to overexpression of hypoxia inducible factor, a transcription factor regulating vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) gene expression. Pazopanib, an angiogenesis inhibitor targeting VEGF receptor, PDGF receptor, and c-KIT, was evaluated in patients with RCC. Patients and Methods: This phase II study was designed as a randomized discontinuation study but was revised to an open-label study on the recommendation of the data monitoring committee (based on week 12 response rate [RR] of 38% in the first 60 patients). The primary end point was changed from progressive disease rate at 16 weeks postrandomization to RR. Pazopanib 800 mg was administered orally once daily. Pazopanib 800 mg was administered orally once daily. Results: The study enrolled 225 patients with metastatic RCC; 155 patients (69%) were treatment naïve, and 70 patients (31%) had received one prior cytokine- or bevacizumab-containing regimen. Overall RR was 35%; median duration of response was 68 weeks. Median progression-free survival (PFS) was 52 weeks. Eastern Cooperative Oncology Group performance status of 0 and time from diagnosis to treatment of more than 1 year were correlated with prolonged PFS. Pazopanib was generally well tolerated. The most common adverse events were diarrhea, fatigue, and hair depigmentation. The most common laboratory abnormalities were elevated AST and ALT. Conclusion: Pazopanib demonstrated durable activity in patients with advanced RCC and was generally well tolerated in this population. These findings support the further development of pazopanib in advanced RCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.21.6994

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 295

Metadata

Authors
Hutson, T. E., Davis, I. D., Machiels, J.-P. H., De Souza, P. L., Rottey, S., Hong, B.-F., Epstein, R. J., Baker, K. L., McCann, L., Crofts, T., Pandite, L., & Figlin, R. A.
Venue
Journal of Clinical Oncology
Published
2010-01-20
Volume
28
Issue
3
Pages
475-480
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2160888189
Cited by
295
References
15
FWCI
26.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2008.21.6994
The paper
Hutson, T. E., Davis, I. D., Machiels, J.-P. H., De Souza, P. L., Rottey, S., Hong, B.-F., Epstein, R. J., Baker, K. L., McCann, L., Crofts, T., Pandite, L., & Figlin, R. A. (2010). Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.6994

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.